In This Article:
-
Revenue: INR553.5 crores for Q2 FY25, a 14% growth year-on-year.
-
H1 FY25 Revenue: INR1,079 crores, a 14% increase compared to H1 FY24.
-
Adjusted EBITDA: INR104.2 crores for Q2 FY25, a 21% growth year-on-year.
-
EBITDA Margin: 18.8% in Q2 FY25, up from 17.8% in Q2 FY24.
-
Pro Forma Revenue Growth: 20% including Vizag acquisition, with an EBITDA margin of 19%.
-
Oncology Business Growth: 20% growth after adjusting for the exited center in MSR, Bangalore.
-
Domestic Business Performance: Strong performance offsetting a 17% decline in international revenue.
-
Digital Channel Revenue: 14% of overall revenue in Q2 FY25, up from 4% in Q2 FY23.
-
Kolkata Imaging Center Revenue Growth: 66% increase in revenue.
-
OPD Footfalls: Increased by 9%, accounting for 18% of revenue.
-
Medical Oncology Growth: 14% increase in chemotherapy sessions.
-
LINAC Machine Utilization: 70% capacity utilization, up from 65% in the previous quarter.
-
Patient Bed Occupancy Rate: 61%.
-
Established Centers Revenue Growth: 13% year-on-year with a 20% growth in EBITDA.
-
Emerging Centers Revenue Growth: 32% increase in revenue for the quarter.
-
ARPOB Growth: Total ARPOB grew by 7.4% to INR45,188.
-
CapEx Spend: INR52 crores for the quarter, with expected CapEx of INR250 crores to INR300 crores in FY25.
Release Date: November 09, 2024
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
-
HealthCare Global Enterprises Ltd (NSE:HCG) reported a robust 14% year-on-year revenue growth for Q2 FY25, reaching INR553.5 crores.
-
The company's adjusted EBITDA crossed INR100 crores for the first time, showing a strong growth of 21% year-on-year.
-
HCG's oncology business experienced impressive 20% growth after adjusting for the exited center in MSR, Bangalore.
-
The company has successfully operationalized a new state-of-the-art 200-bedded comprehensive cancer care center in Ahmedabad.
-
Digital initiatives have significantly boosted patient acquisition, with digital channel revenue rising to 14% of overall revenue in Q2 FY25, up from 4% in Q2 FY23.
Negative Points
-
International revenue declined by 17% due to geopolitical challenges in markets like Bangladesh.
-
The South Mumbai center faced challenges due to a decline in international business, impacting overall performance.
-
The company incurred a loss of INR3.8 crores to INR4 crores in the South Bombay hospital for the first half of FY25.
-
There was a one-time other income of INR5 crores, which will not continue in future quarters.
-
The company is facing challenges in achieving double-digit ROCE in emerging centers, particularly in South Mumbai.